2018 George and Christine Sosnovsky Award in Cancer Therapy Winner


Professor Margaret Brimble
Professor Margaret Brimble
The University of Auckland, New Zealand

 

Awarded for developing a novel innovative chemistry platform to generate fully-synthetic, self-adjuvanting cancer vaccines for the treatment of different cancers

 


About the Winner


Margaret Brimble is the Director of Medicinal Chemistry and a Distinguished Professor at the University of Auckland, New Zealand where her research program focuses on the synthesis of bioactive natural products, and peptides as potential new medicines. 

She has published more than 460 papers, 60 reviews and is an inventor on 30+ patents. She has been awarded the 2016 Marsden Medal, 2012 RSNZ Rutherford (NZ's top science prize), MacDiarmid and Hector Medals, 2011 Royal Australian Chemical Institute Adrien Albert Award, 2010 RSC Natural Products Award, 2007 L'Oreal-UNESCO Women in Science laureate in Materials Science for Asia-Pacific, 2015 IUPAC Distinguished Women in Chemistry Award and conferred the Queen's Honour CNZM in 2012 for service to science. She is Past-President of IUPAC Organic and Biomolecular Division III, an Associate Editor for Organic and Biomolecular Chemistry, Past-President of the International Society for Heterocyclic Chemistry and Past-Chair of the Rutherford Foundation RSNZ. 

She discovered the first drug "trofinetide" to treat Rett Syndrome that is in phase III clinical trials with Neuren Pharmaceuticals. Trofinetide is New Zealand's first successful drug and one of only a few to be discovered in an academic laboratory. Margaret also co-Founded the spin-out company SapVax that is using her innovative peptide lipidation chemistry to generate self-adjuvanting cancer vaccines


Related Links

Link icon Professor Brimble's Webpage
The University of Auckland

Link icon SapVax
Professor Brimble's spin-out company


External links will open in a new browser window